NCT07102394View on ClinicalTrials.gov

Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
NF1NeurofibromatosisCutaneous NeurofibromaNeurofibromaVon Recklinghausen DiseaseNeurofibromas
Interventions
DRUG

Imlygic

intralesional administration of IMLYGIC administered on Days 1 and 21 of each cycle for 4 cycles (8 treatments).

Trial Locations (1)

21287

Johns Hopkins University, Baltimore

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Neurofibromatosis Therapeutic Acceleration Program

UNKNOWN

collaborator

Amgen

INDUSTRY

lead

Johns Hopkins University

OTHER

NCT07102394 - Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 | Biotech Hunter | Biotech Hunter